Ivermectin Attenuates CCl₄-Induced Liver Fibrosis in Mice by Suppressing Hepatic Stellate Cell Activation.

ABSTRACT: Liver fibrosis, a common liver dysfunction with high morbidity and mortality rates, is the leading cause of cirrhosis and hepatocellular carcinoma, for which there are no effective therapies. Ivermectin is an antiparasitic drug that also has been showing therapeutic actions in many other diseases, including antiviral and anticancer actions, as well as treating metabolic diseases. Herein, we evaluated the function of ivermectin in regulating liver fibrosis. Firstly, carbon tetrachloride (CCl₄)-injected Balb/c mice were used to assess the antifibrosis effects of ivermectin in vivo. Further, CFSC, a rat hepatic stellate cell (HSC) line, was used to explore the function of ivermectin in HSC activation in vitro. The in vivo data showed that ivermectin administration alleviated histop

SUBMITTER: Ying H 

PROVIDER: S-EPMC9782196 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature